表皮生长因子受体突变型非小细胞肺癌：治疗序列图。
EGFR-mutated NSCLC: A roadmap to treatment sequences.
机构信息
Institut Curie, Paris, France; Paris Saclay University, UVSQ, Faculté de Médecine Simone Veil, Versailles, France.
出版信息
Med. 2024 Sep 13;5(9):1044-1047. doi: 10.1016/j.medj.2024.07.010.
PMID:39276767
Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for the management of EGFR-mutated non-small cell lung cancer. Recent results from the HARMONi-A trial lead to considering ivonescimab-a first-in-class, bispecific antibody targeting PD-1 and VEGF-plus chemotherapy as a new second-line option following third-generation TKIs.
摘要
表皮生长因子受体 (EGFR) 酪氨酸激酶抑制剂 (TKI) 是 EGFR 突变型非小细胞肺癌治疗的标准方案。最近 HARMONi-A 试验的结果表明，针对 PD-1 和 VEGF 的双特异性抗体伊沃西单抗-一种首创的药物联合化疗可作为第三代 TKI 后的新二线选择。
Zotero 插件